Medpace Holdings Inc vs ArcelorMittal SA — how do they compare? Medpace Holdings Inc trades at $605.78 (market cap $16.81B), while ArcelorMittal SA trades at $74.26 (market cap $55.96B). The key difference: ArcelorMittal SA is far larger — about 3.3× Medpace Holdings Inc's market cap, and ArcelorMittal SA pays a 0.81% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | MT | |
|---|---|---|
Market Cap | $16.81B | $55.96B |
Sector | Technology | Basic Materials |
52-Week High | $620.59 | $75.35 |
52-Week Low | $393.42 | $32.44 |
Enterprise Value | $16.43B | $65.53B |
Dividend Yield | — | 0.81% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $590.67, up 0.97% on the day, near its consensus price target of $599.57. The stock shows bullish momentum with a golden cross formation and strong institutional interest, while recent Q2 2026 earnings beat estimates with EPS of $4.25 versus $3.98 expected. Revenue growth remains robust, projected to rise from $2.53 billion in 2025 to $2.8 billion in 2026, supporting a premium valuation with a P/E of 35.4.
Outlook is positive given earnings consistency and raised 2026 guidance, but risks include high valuation sensitivity and a shareholder lawsuit investigation. The stock offers growth potential from a strong backlog and net book-to-bill ratio of 1.13x, though investors should monitor legal developments and competitive pressures in medical services.
ArcelorMittal (MT) trades at $73.29, up 0.1% with bullish technical signals from moving averages despite recent earnings miss. The company shows improving fundamentals with Q2 2026 revenue growth and strong cash flow generation of $4.8B from operations. Recent corporate developments include dividend payments and strategic partnerships with Microsoft, while analyst consensus remains positive with 50% buy ratings.
Outlook remains cautiously optimistic with European business recovery potential, though risks include cyclical steel demand volatility and elevated debt levels. The stock offers value with reasonable P/S (0.89) and P/B (1.01) ratios, but investors should monitor execution on second-half shipment guidance and margin pressures from input costs.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →